TC
ASPX

TFS Capital’s AUSPEX PHARMACEUTICALS INC COM STK (DE) ASPX Stock Holding History

TFS Capital’s Portfolio ASPX Stock Details ASPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-18,437
Closed -$473K – 1340
2014
Q3 		$473K Buy
+18,437
New +$392K 0.04% 615

Other funds holding ASPX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TFS Capital's ASPX Position: Q4 2014 in Review

TFS Capital sold out of AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) in Q4 2014, closing a stake of 18,437 shares — an estimated $473K sold.

TFS Capital first reported a position in ASPX in Q3 2014 and held it in 1 quarter. The position peaked at $473K in Q3 2014. 89 funds tracked by Wall St. Rank hold ASPX as of Q4 2014.

  • TFS Capital reported no remaining AUSPEX PHARMACEUTICALS INC COM STK (DE) position as of Q4 2014 after selling out during the quarter.
  • TFS Capital sold 18,437 AUSPEX PHARMACEUTICALS INC COM STK (DE) shares in Q4 2014, an estimated $473K.
  • TFS Capital first reported a position in AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q3 2014 and held it in 1 quarter.
  • TFS Capital's AUSPEX PHARMACEUTICALS INC COM STK (DE) position peaked at $473K in Q3 2014.
  • 89 funds tracked by Wall St. Rank held AUSPEX PHARMACEUTICALS INC COM STK (DE) as of Q4 2014.

Based on TFS Capital's 13F filing for Q4 2014, filed 29 Jan 2015.